Revolutionizing Healthcare: NanoPass Technologies Raises $4M in Series A Funding to Fuel Intradermal Precision Innovation

NanoPass Technologies, a leader in intradermal delivery innovation, has successfully raised $4 million in its latest round of financing, spearheaded by Israel Health Care Ventures (IHCV).

This newly acquired funding will not only bolster NanoPass’s production capabilities but also significantly amplify its ongoing research and development efforts aimed at enhancing the MicronJet™ platform.

Recognized globally for its precision and efficacy, the MicronJet™ is the premier hollow microneedle device, having undergone over 50 clinical studies and recently achieving remarkable results in intradermal flu vaccine efficacy.

By utilizing only 20% of the traditional dose, NanoPass's innovative approach demonstrates equivalent or superior immunogenicity, paving the way for more efficient vaccine delivery systems.

The strategic backing from prominent investors, including Ofer Hi-Tech, D-Partners, WFD Ventures, and Elcam Medical, highlights the confidence in NanoPass's mission to transform healthcare practices.

The funds raised will facilitate joint clinical development projects with leading pharmaceutical companies, allowing NanoPass to expand its reach into new therapeutic areas.

The company is committed to its vision of a "Precision Revolution" in intradermal delivery, and this funding marks a significant step forward in its journey to reshape the landscape of therapeutic and medical aesthetic procedures.

With the increasing global demand for innovative healthcare solutions, NanoPass Technologies stands at the forefront, ready to deliver safe, precise, and efficient alternatives.